{ "tag": [ "compiled" ], "id": "ocds-h6vhtk-0371b3-2022-09-30T11:32:35+01:00", "date": "2022-09-30T11:32:35+01:00", "ocid": "ocds-h6vhtk-0371b3", "initiationType": "tender", "tender": { "id": "DN621227", "legalBasis": { "id": "32014L0024", "scheme": "CELEX" }, "title": "(NU/1433-36) IndigoDX Ltd: Commercialisation of university research through provision of management skills to assist in successful spin-out company creation", "status": "complete", "classification": { "scheme": "CPV", "id": "79400000", "description": "Business and management consultancy and related services" }, "mainProcurementCategory": "services", "description": "1 in 5 adults in the UK suffer from urinary symptoms caused by an overactive bladder (OAB). Symptoms include urgency (a sudden compelling desire to pass urine, which cannot be deferred), increased frequency of voiding (both day and night) and urge incontinence (involuntary leakage accompanied by / immediately preceded by urgency). The Team wishes to establish a spinout company to produce a Dipstick-style test. Our discovery is currently being developed into a simple-to-use diagnostic tool used for (1) regular screening for OAB in adults, at a GP surgery, pharmacy or nursing home, and (2) to assess the effectiveness of treatments (companion diagnostic) and modifying dosing/treatments accordingly. Accurate and early diagnosis will improve treatment outcomes, eliminating the need for patients to have invasive and high-risk surgery-led second-line treatments necessary for advanced-stage disease. Currently there is no competition for a non-invasive biomarker-based test, and new product development activity appears to be very limited, suggesting an opportunity for 'first mover advantage' and to establish a standard. We require a driven executive to take this technology forward and build a compelling proposition for investment. The Executive will need to create a robust business model that is acceptable to the founders, develop and deliver pitch materials for investors and establish collaborative research projects. The executive appointed should have an appropriate background, ideally with experience of high tech starts ups, securing seed investment and establishing manufacturing facilities.", "lots": [ { "id": "1", "description": "1 in 5 adults in the UK suffer from urinary symptoms caused by an overactive bladder (OAB). Symptoms include urgency (a sudden compelling desire to pass urine, which cannot be deferred), increased frequency of voiding (both day and night) and urge incontinence (involuntary leakage accompanied by / immediately preceded by urgency). The Team wishes to establish a spinout company to produce a Dipstick-style test. Our discovery is currently being developed into a simple-to-use diagnostic tool used for (1) regular screening for OAB in adults, at a GP surgery, pharmacy or nursing home, and (2) to assess the effectiveness of treatments (companion diagnostic) and modifying dosing/treatments accordingly. Accurate and early diagnosis will improve treatment outcomes, eliminating the need for patients to have invasive and high-risk surgery-led second-line treatments necessary for advanced-stage disease. Currently there is no competition for a non-invasive biomarker-based test, and new product development activity appears to be very limited, suggesting an opportunity for 'first mover advantage' and to establish a standard. We require a driven executive to take this technology forward and build a compelling proposition for investment. The Executive will need to create a robust business model that is acceptable to the founders, develop and deliver pitch materials for investors and establish collaborative research projects. The executive appointed should have an appropriate background, ideally with experience of high tech starts ups, securing seed investment and establishing manufacturing facilities.", "awardCriteria": { "criteria": [ { "name": "Ability to meet the required programme", "type": "quality", "description": "Pass / Fail" }, { "name": "Confirm acceptance of the formal appointment to the board milestone requirements", "type": "quality", "description": "Pass / Fail" }, { "name": "Quality: Ability to meet the Job Description required for the individual", "type": "quality", "description": "70" }, { "name": "Equity share", "type": "quality", "description": "5" }, { "type": "price", "description": "25" } ] }, "hasOptions": false, "status": "cancelled" } ], "items": [ { "id": "1", "deliveryAddresses": [ { "region": "UKC" } ], "relatedLot": "1" } ], "procurementMethod": "selective", "procurementMethodDetails": "Restricted procedure", "techniques": { "hasDynamicPurchasingSystem": true }, "reviewDetails": "The University will incorporate a standstill period at the point information on the award of the contract is communicated to tenderers. That notification will provide full information on the award decision. The standstill period, which will be for a minimum of 10 calendar days, provides time for unsuccessful tenderers to challenge the award decision before the contract is entered into. The Public Contracts Regulations 2015 (SI 2015 No 102) provide for aggrieved parties who have been harmed or are at risk of harm by a breach of the rules to take action in the High Court (England, Wales and Northern Ireland) within 30 days of knowledge or constructive knowledge of breach." }, "awards": [ { "id": "027450-2022-1", "relatedLots": [ "1" ], "status": "active", "suppliers": [ { "id": "GB-FTS-64819", "name": "DU Biosciences" } ] } ], "parties": [ { "id": "GB-FTS-168", "name": "Newcastle University", "identifier": { "legalName": "Newcastle University" }, "address": { "streetAddress": "Newcastle University, Procurement Services, Kingsgate", "locality": "Newcastle", "region": "UKC", "postalCode": "NE1 7RU", "countryName": "United Kingdom" }, "contactPoint": { "name": "Mrs Natalie Morton", "telephone": "+44 1912086396", "email": "natalie.morton@ncl.ac.uk" }, "roles": [ "buyer", "centralPurchasingBody" ], "details": { "url": "https://www.ncl.ac.uk", "buyerProfile": "https://www.ncl.ac.uk", "classifications": [ { "scheme": "TED_CA_TYPE", "id": "BODY_PUBLIC", "description": "Body governed by public law" }, { "scheme": "COFOG", "id": "09", "description": "Education" } ] } }, { "id": "GB-FTS-169", "name": "Durham University", "identifier": { "legalName": "Durham University" }, "address": { "locality": "The Palatine Centre, Stockton Road", "region": "UKC", "countryName": "United Kingdom" }, "contactPoint": { "email": "Edwin.e.milligan@durham.ac.uk" }, "roles": [ "buyer" ], "details": { "url": "https://www.durham.ac.uk" } }, { "id": "GB-FTS-64818", "name": "Northumbria University Newcastle Newcastle", "identifier": { "legalName": "Northumbria University Newcastle Newcastle" }, "address": { "locality": "Newcastle upon Tyne", "region": "UKC", "countryName": "United Kingdom" }, "contactPoint": { "email": "Hugh.Rhodes@northumbria.ac.uk" }, "roles": [ "buyer" ], "details": { "url": "https://northumbria.ac.uk" } }, { "id": "GB-FTS-171", "name": "University of Sunderland", "identifier": { "legalName": "University of Sunderland" }, "address": { "locality": "Sunderland", "region": "UKC", "countryName": "United Kingdom" }, "contactPoint": { "email": "Cheryl.Holmstrom@sunderland.ac.uk" }, "roles": [ "buyer" ], "details": { "url": "https://Sunderland.ac.uk" } }, { "id": "GB-FTS-38690", "name": "Teesside University", "identifier": { "legalName": "Teesside University" }, "address": { "locality": "Middlesbrough, Tees Valley", "region": "UKC", "countryName": "United Kingdom" }, "contactPoint": { "email": "David.Pratt@tees.ac.uk" }, "roles": [ "buyer" ], "details": { "url": "https://www.tees.ac.uk/" } }, { "id": "GB-FTS-38691", "name": "University of Bath on behalf of the SETsquared", "identifier": { "legalName": "University of Bath on behalf of the SETsquared" }, "address": { "locality": "Claverton Down, Bath", "region": "UK", "countryName": "United Kingdom" }, "contactPoint": { "email": "pb487@bath.ac.uk" }, "roles": [ "buyer" ], "details": { "url": "https://www.bath.ac.uk/" } }, { "id": "GB-FTS-172", "name": "European Union", "roles": [ "funder" ] }, { "id": "GB-FTS-64819", "name": "DU Biosciences", "identifier": { "legalName": "DU Biosciences" }, "address": { "locality": "London", "region": "UKC", "postalCode": "SW19 1JG", "countryName": "United Kingdom" }, "roles": [ "supplier" ], "details": { "scale": "sme" } }, { "id": "GB-FTS-174", "name": "Newcastle University", "identifier": { "legalName": "Newcastle University" }, "address": { "locality": "Tyne and Wear", "postalCode": "NE1 7RU", "countryName": "United Kingdom" }, "roles": [ "reviewBody" ] }, { "id": "GB-FTS-1062", "name": "Newcastle University", "identifier": { "legalName": "Newcastle University" }, "address": { "locality": "Tyne and Wear", "countryName": "United Kingdom" }, "roles": [ "mediationBody", "reviewContactPoint" ] } ], "buyer": { "id": "GB-FTS-168", "name": "Newcastle University" }, "planning": { "budget": { "finance": [ { "id": "1", "description": "Northern Accelerator programme involving funding from both the European Regional Development Funding (ERDF) and Research England", "financingParty": { "name": "European Union", "id": "GB-FTS-172" }, "relatedLots": [ "1" ] } ] } }, "contracts": [ { "id": "027450-2022-1", "awardID": "027450-2022-1", "status": "active", "value": { "amount": 30000, "currency": "GBP" }, "dateSigned": "2022-09-06T00:00:00+01:00" } ], "bids": { "statistics": [ { "id": "1", "measure": "bids", "relatedLot": "1", "value": 1 }, { "id": "2", "measure": "smeBids", "relatedLot": "1", "value": 1 }, { "id": "3", "measure": "foreignBidsFromEU", "relatedLot": "1", "value": 0 }, { "id": "4", "measure": "foreignBidsFromNonEU", "relatedLot": "1", "value": 1 }, { "id": "5", "measure": "electronicBids", "relatedLot": "1", "value": 1 } ] }, "links": [ { "rel": "prev", "href": "https://ted.europa.eu/udl?uri=TED:NOTICE:528050-2022:TEXT:EN:HTML" } ], "language": "en" }